Alirocumab
Alirocumab is a pharmaceutical drug with 63 clinical trials. Currently 7 active trials ongoing. Historical success rate of 95.6%.
Success Metrics
Based on 43 completed trials
Phase Distribution
Phase Distribution
7
Early Stage
12
Mid Stage
38
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
93.5%
43 of 46 finished
6.5%
3 ended early
7
trials recruiting
63
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Impact of Alirocumab on Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic Events
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers
Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)
Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention
Clinical Trials (63)
Impact of Alirocumab on Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic Events
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers
Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)
Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention
Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid Plaque
Cardiac Allograft Vasculopathy Inhibition With Alirocumab
TOP 2301: Neoadjuvant Chemo for NSCLC
Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)
Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
Trial of PCSK9 Inhibition in Patients with Acute Stroke and Symptomatic Intracranial Atherosclerosis
Alirocumab in Patients with Sepsis
Pharmacodynamic Biomarkers to Support Biosimilar Development: PCSK9 Inhibitors
Extra Alirocumab in Addition to Statin Therapy in Asymptomatic Intracranial Atherosclerotic Stenosis (EAST-aICAS)
The Effect of Early Administration of PCSK9 Inhibitor to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile
Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant Recipients
Extra Alirocumab in Addition to Statin Therapy in Symptomatic IntraCranial Atherosclerotic Stenosis ----a Pilot Study
A Trial of Alirocumab and Plaque Regression in Peripheral Arterial Disease
Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 63